LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Akciju saraksts・Compugen Ltd

Compugen Ltd

Slēgts

2.03 -2.87

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

Max

2.12

Galvenie mērījumi
By Trading Economics
Ienākumi	-65M -7.7M
Pārdošana	-65M 2.2M
P/E Sektora vidējais	6.474 49.888
EPS	-0.08
Peļņas marža	-352.436
Darbinieki	75
EBITDA	-64M -7.7M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+138.1% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-38M 233M
Iepriekšējā atvēršanas cena	4.9
Iepriekšējā slēgšanas cena	2.03

Compugen Ltd Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 8. jūn. 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

2026. g. 8. jūn. 15:41 UTC

Galvenie tirgus virzītāji

American Battery Shares Jump on Energy Department Victory

2026. g. 8. jūn. 23:46 UTC

Tirgus saruna

Nikkei May Rebound After Monday's Selloff -- Market Talk

2026. g. 8. jūn. 23:37 UTC

Tirgus saruna

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

2026. g. 8. jūn. 23:25 UTC

Tirgus saruna

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

2026. g. 8. jūn. 23:25 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 8. jūn. 21:57 UTC

Iegādes, apvienošanās, pārņemšana

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

2026. g. 8. jūn. 21:56 UTC

Iegādes, apvienošanās, pārņemšana

Salesforce Agrees to Buy m3ter

2026. g. 8. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 8. jūn. 19:22 UTC

Tirgus saruna

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

2026. g. 8. jūn. 19:01 UTC

Tirgus saruna

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

2026. g. 8. jūn. 18:52 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 8. jūn. 18:52 UTC

Tirgus saruna

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

2026. g. 8. jūn. 18:17 UTC

Tirgus saruna

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

2026. g. 8. jūn. 17:32 UTC

Tirgus saruna

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

2026. g. 8. jūn. 17:29 UTC

Tirgus saruna

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

2026. g. 8. jūn. 17:29 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 8. jūn. 16:55 UTC

Iegādes, apvienošanās, pārņemšana

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

2026. g. 8. jūn. 16:54 UTC

Iegādes, apvienošanās, pārņemšana

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

2026. g. 8. jūn. 16:40 UTC

Tirgus saruna

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

2026. g. 8. jūn. 16:31 UTC

Tirgus saruna

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

2026. g. 8. jūn. 16:27 UTC

Tirgus saruna

Mexican Inflation Seen Easing in May -- Market Talk

2026. g. 8. jūn. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 8. jūn. 16:03 UTC

Iegādes, apvienošanās, pārņemšana

Orange Bought Stake From Lorca

2026. g. 8. jūn. 16:01 UTC

Iegādes, apvienošanās, pārņemšana

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

2026. g. 8. jūn. 16:01 UTC

Iegādes, apvienošanās, pārņemšana

Orange Acquires 100% Ownership of MasOrange

2026. g. 8. jūn. 15:58 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 8. jūn. 15:58 UTC

Tirgus saruna

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

2026. g. 8. jūn. 15:55 UTC

Tirgus saruna

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

2026. g. 8. jūn. 15:41 UTC

Tirgus saruna

Gold Falls Below 200-Day Moving Average -- Market Talk

Salīdzinājums

Cenas izmaiņa

Compugen Ltd Prognoze

Cenas mērķis

By TipRanks

138.1% augšup

Prognoze 12 mēnešiem

Vidējais 5 USD 138.1%

Augstākais 6 USD

Zemākais 4 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Compugen Ltd — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Compugen Ltd — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.